Enveric Biosciences (ENVB) announced that it has received a notice of allowance from the United States Patent and Trademark Office for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Enveric Biosciences receives notice of allowance from USPTO for EVM401
- Psychedelic: Clearmind reports results from first cohort in AUD trial
- Enveric Biosciences Regains Nasdaq Compliance
- Enveric Biosciences trading halted, news pending
- Upcoming Stock Splits This Week (October 27 to October 31) – Stay Invested